Morgan Stanley Sees Focus & Efficiency as Key for Integra Lifesciences

In a report published Wednesday, Morgan Stanley analyst David R. Lewis reiterated an Equal-Weight rating on Integra Lifesciences IART. In the report, Morgan Stanley noted, “Integra adjusted ‘14 guidance to sales of $920-$940mn and EPS of $3.00-$3.18. The shift was largely a reflection of potential confluent competition, distributor changes, and less momentum in its hospital based business. The shift down does not fundamentally alter our view on Integra or the Confluent acquisition and we still see Confluent accretion approaching $0.30 for 2015.” Integra Lifesciences closed on Tuesday at $45.84.